Is Spero Therapeutics, Inc. (SPRO) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 3.3% / 30% | 40.8% / 30% | 40.5% / 30% | 17.28% / 5% | ✗ NOT HALAL |
| DJIM | 3.3% / 33% | 40.8% / 33% | 40.5% / 33% | 17.28% / 5% | ✗ NOT HALAL |
| MSCI | 3.9% / 33% | 47.8% / 33% | 47.5% / 33% | 17.28% / 5% | ✗ NOT HALAL |
| S&P | 3.3% / 33% | 40.8% / 33% | 40.5% / 33% | 17.28% / 5% | ✗ NOT HALAL |
| FTSE | 3.9% / 33% | 47.8% / 33% | 47.5% / 50% | 17.28% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -52.2% | |
| Operating Margin | -134.7% | |
| Net Margin | -108.1% | |
| Return on Equity (ROE) | -95.3% | |
| Return on Assets (ROA) | -29.8% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$23M |
| Free Cash Flow | -$23M |
| Total Debt | $4M |
| Debt-to-Equity | 12.6 |
| Current Ratio | 3.8 |
| Total Assets | $111M |
Price & Trading
| Last Close | $2.37 |
| 50-Day MA | $2.35 |
| 200-Day MA | $2.34 |
| Avg Volume | 296K |
| Beta | 1.5 |
|
52-Week Range
$0.51
| |
About Spero Therapeutics, Inc. (SPRO)
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Spero Therapeutics, Inc. (SPRO) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Spero Therapeutics, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Spero Therapeutics, Inc.'s debt ratio?
Spero Therapeutics, Inc.'s debt ratio is 3.3% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 3.9%.
What are Spero Therapeutics, Inc.'s key financial metrics?
Spero Therapeutics, Inc. has a market capitalization of $135M, trailing P/E ratio of 15.5, and revenue of $27M. The company maintains a gross margin of -52.2% and a net margin of -108.1%. Return on equity stands at -95.3%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.